Subscribe
cancer
wildpixel / iStockphoto.com
28 July 2020BiotechnologyMuireann Bolger

University can claim sovereign immunity in cancer treatment suit, rules Federal Circuit

The dispute arises from the biotechnology company Gensetix’s acquisition of exclusive licencing of US patent numbers 8,728,806 and 9,333,248 from the University of Texas in 2014.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Is the Allergan patent deal a misuse of sovereign immunity?
19 September 2017   Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Is the Allergan patent deal a misuse of sovereign immunity?
19 September 2017   Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

More on this story

Americas
Is the Allergan patent deal a misuse of sovereign immunity?
19 September 2017   Earlier this month, in a bid to obtain immunity against an inter partes review (IPR), Allergan transferred its patent rights for a dry eye treatment to a Native American tribe.
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug